Correlation Between Ambu AS and Orphazyme
Can any of the company-specific risk be diversified away by investing in both Ambu AS and Orphazyme at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ambu AS and Orphazyme into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ambu AS and Orphazyme AS, you can compare the effects of market volatilities on Ambu AS and Orphazyme and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ambu AS with a short position of Orphazyme. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ambu AS and Orphazyme.
Diversification Opportunities for Ambu AS and Orphazyme
Average diversification
The 3 months correlation between Ambu and Orphazyme is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding Ambu AS and Orphazyme AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Orphazyme AS and Ambu AS is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ambu AS are associated (or correlated) with Orphazyme. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Orphazyme AS has no effect on the direction of Ambu AS i.e., Ambu AS and Orphazyme go up and down completely randomly.
Pair Corralation between Ambu AS and Orphazyme
Assuming the 90 days trading horizon Ambu AS is expected to under-perform the Orphazyme. But the stock apears to be less risky and, when comparing its historical volatility, Ambu AS is 1.85 times less risky than Orphazyme. The stock trades about -0.1 of its potential returns per unit of risk. The Orphazyme AS is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest 85,000 in Orphazyme AS on September 3, 2024 and sell it today you would earn a total of 13,000 from holding Orphazyme AS or generate 15.29% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Ambu AS vs. Orphazyme AS
Performance |
Timeline |
Ambu AS |
Orphazyme AS |
Ambu AS and Orphazyme Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Ambu AS and Orphazyme
The main advantage of trading using opposite Ambu AS and Orphazyme positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ambu AS position performs unexpectedly, Orphazyme can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Orphazyme will offset losses from the drop in Orphazyme's long position.Ambu AS vs. Bavarian Nordic | Ambu AS vs. Genmab AS | Ambu AS vs. GN Store Nord | Ambu AS vs. DSV Panalpina AS |
Orphazyme vs. Zealand Pharma AS | Orphazyme vs. Ambu AS | Orphazyme vs. BioPorto | Orphazyme vs. Bavarian Nordic |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
CEOs Directory Screen CEOs from public companies around the world |